Bo Ning, Ph. D.
Email: [email protected] Assistant Research Professor Center for Molecular Design and Biomimetics Tel: 480-965-0859 Biodesign Institute, Arizona State University 1001 S. McAllister Ave. B130B Tempe, AZ 85287-5001
RESEARCH INTERESTS • Cancer immunotherapy • T cell function and regulation • Tumor specific T cells and TCR • Epigenetic regulation in stem cells, cancers and immune system • Immune cell metabolism • Stem cell and development • Cancer stem cells • DNA nanotechnologies in cancer immunotherapy
EDUCATION Ph.D., Molecular biology/ Physical chemistry (Advisor: Dr. Yuanfang Liu) 09/2009–06/2012 Academy for Advanced Interdisciplinary Studies, Peking University, P.R. China Ph.D., Molecular biology/ Physical chemistry (Advisor: Dr. Guangjun Nie) 09/2009–06/2012 National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, P.R. China M.S., Biochemistry and molecular biology 09/2005–06/2008 Jilin University, P.R. China B.S., Biotechnology 09/2000–06/2004 Jilin University, P.R . C hina
PERSONAL STATEMENT: I have a strong background in immunology, biochemistry, molecular biology, and diagnostics, as represented by my Ph.D., which was jointly awarded by the National Centers for Nanoscience and Technology of China and Peking. These two institutions focus on cutting-edge interdisciplinary research in biomedical studies and nanotechnology. My Ph.D. research has a multidisciplinary span, covering hematopoietic stem cell biology and the development of platinum-nanoparticle-biomolecule enzymes. My current research has a similar focus on medical applications, covering epigenetic regulation of stem cells, innate immune signaling of viral infections and cancer, and T cell-mediated cancer immunotherapy, including mechanisms and applications of T cells in cancer immunotherapy, mutated antigen discovery, and cancer vaccine development. I am both ready and eager to begin my career as an independent researcher to further develop and promote my contributions to immunotherapy studies.
PROFESSIONAL EXPERIENCE Research experience Houston Methodist Research Institute, Center for Inflammation and Epigenetic, Houston, TX Postdoc Fellow (with Dr. Rongfu Wang) 10/2012–present • Cancer immunotherapy and mouse models • Enhance T cell functions by blocking inhibitory molecules • Tumor specific TCR cloning and mutated antigen discovery Ning, Bo CV, Page 2
• Single cell sequencing and cloning • Single chain TCR design and cloning • Universal T cell for cancer immunotherapy • Epigenetic regulation mechanisms in ES cell differentiation and iPSC reprogramming • Metabolic regulations of immune cells • Epigenetic regulation mechanisms in neuroblastoma, glioma and breast cancer • Cancer stem cells in breast cancer, prostate cancer and neuroblastoma • Intestine organoids culture and inflammation model National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, P.R. China Ph.D. student (with Dr. Guangjun Nie and Dr. Yuanfang Liu) 09/2009–06/2012 • Epigenetic regulations, iron metabolism of heme biosynthesis in hematopoietic stem cells • Global DNA methylation measurements by mass spectrometry • Catalase activities of ferritin-platinum nanoparticles • PCR based detection for infection diseases • Cytosolic ferritin degradation pathways and mechanisms • Iron transporter ferropotin functions in macrophages and inflammatory responses • Neuroprotective functions of mitochondrial ferritin Jilin University, Molecular Enzyme Engineering Laboratory, P.R . C h in a M.S. student (with Dr. Dongyun Hao) 09/2005–06/2008 • Differential proteomics research in asthma • Cold resistance gene CBF1 cloning from Adonis
FUNDING
1. Dottie and Jimmy C. Adair Myelodysplastic Syndrome Research and Treatment Fund (2016-2017): Mutated genes based precision medicine for MDS therapy (Co-PI, $50,000) 2. Dottie and Jimmy C. Adair Myelodysplastic Syndrome Research and Treatment Fund (2015-2016): Cellular Epigenetic Reprogramming and Differentiation in Myelodysplastic Syndromes (Project leader, $50,000)
AWARDS
1. Graduate Student Travel Award to attend Annual meeting of American Society of Hematology, 2010, Orlando 2. Director’s Scholarship of the NCNST, 2010 3. Director’s Scholarship of the NCNST, 2011 4. Distinguished student presenter in Academy Annual meeting of the NCNST, 2011 Technologies 1. Human T cells: TIL and T cell clone culture and expansion, FACS, ELISA, LDH assays, FACS, lentivirus or retrovirus infection. 2. Mouse experiments: bone marrow, spleen and lymph node cell isolation; Tumor mouse model setup, T cell therapy in mouse model. 3. Molecular cloning: TCR cloning, plasmid construction, Gateway system 4. Gene knockdown and knockout: siRNA/shRNA design and usage, CRISPR-Cas9 technology 5. Epigenetic regulation research: ChIP-PCR, ChIP-seq, bisulfite sequencing, methylation specific PCR 6. Stem cell: human and mouse ESCs culture and characterization, mouse and human HSC culture and in vitro differentiation; 3D organoid culture 7. Basic molecular biology: PCR and real-time PCR, western blotting, Co-IP, lentivirus and retrovirus packaging Peer-reviewed publications 1. Ning, B., Liu, G., Liu, Y., Su, X., Anderson, G. J., Zheng, X., Chang, Y., Guo, M., Zhao, Y., and Nie, G. 5- aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear
Ning, Bo CV, Page 3
localization and binding to the E-boxes of TfR1 and ferrochelatase genes. (2011) J Biol Chem 286, 43, 37196–37206 2. Ning, B., Zhao, W. Qian, C., Liu, P., Li, Q., Li, W., and Wang, R. (2017) Usp26 Functions as a Negative Regulator of Cellular Reprogramming by Regulating PRC1 Complexes, Nature communications, accepted, 3. Ning, B., Li, W.Y., Zhao, W. and Wang, R.F. (2016), Targeting Epigenetic Regulators in Cancer. Acta Biochimica et Biophysica Sinica, 48, (1), 97-109 4. Liu F, Huang J, Ning B, Liu Z, Chen S. (2016) Drug discovery via human-derived stem cell organoids. Front. Pharmacol 5. Zhao, W., Ning, B., and Qian, C. (2014). Regulatory factors of induced pluripotency: current status. Stem Cell Investigation, 1, 7, 6. Fan, J., Yin, J. J., Ning, B., Wu, X., Hu, Y., Ferrari, M., Anderson, G. J., Wei, J., Zhao, Y., and Nie, G. Direct evidence for catalase and peroxidase activities of ferritin-platinum nanoparticles. (2011) Biomaterials 32, 1611-1618 7. Zhang, Z., Zhang, F., An, P., Guo, X., Shen, Y., Tao, Y., Wu, Q., Zhang, Y., Yu, Y., Ning, B., Nie, G., Knutson, M. D., Anderson, G. J., and Wang, F. (2011) Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood 118, 1912-1922 8. Zhang, Y., Mikhael, M., Xu, D., Li, Y., Soe-Lin, S., Ning, B., Li, W., Nie, G., Zhao, Y., and Ponka, P. (2010) Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxidants & redox signaling 13, 999-1009 9. Shi, Z. H., Nie, G., Duan, X. L., Rouault, T., Wu, W. S., Ning, B., Zhang, N., Chang, Y. Z., and Zhao, B. L. (2010) Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. Antioxidants & redox signaling 13, 783-796 10. Nie, G., Zhu, M., and Ning, B. Application of nuclear analytical techniques for iron-omics studies. (2010), RSC Publishing, Nuclear Analytical Techniques for Metallomics and Metalloproteomics, Chapter 8, 239-264 11. Huo, R. Shi, Y. Xu, J., Yan, F., LÜ, S., Su, J., Duan, Y., Fan, J., Ning, B. Wei, J. Antioxidant effect of human selenium-containing single-chain Fv in rat cardiac myocytes, 2009, Chem Res Chinese Universities 25 (2), 216-219
PRESENTATIONS 1. Poster presentation: Porto, Portugal, Bioiron Annual Meeting, Lysosomal Proteolysis Is The Primary Degradation Pathway For Cytosolic Ferritin And Is Necessary For Iron Exit From Ferritin 2. Poster presentation: Orlando, American Society of Hematology Annual Meeting, Regulation of Iron Metabolism: Poster session II “TfR1 and Ferrochelatase Expression During Erythroid Differentiation Induced by 5-Aza-Cdr In Both MEL Cells and BFU-E-Derived Erythroblasts Correlates with c-Myc Function” 2010, 3. Poster presentation: 2011, Vancouver, Canada, Bioiron Annual Meeting, 5-aza-2’-deoxycytidine Activates Iron Uptake And Heme Biosynthesis Via Increasing C-myc Nuclear Localization And Binding To The E-box Of Tfr1 4. Oral presentation: 2011, Xi’an, China, Annual conference of mitochondria, “Epigenetic regulation of erythropoiesis and mitochondrial iron metabolism” 5. Oral presentation: 2011, Beijing, Academy Annual meeting of the NCNST, “Epigenetic regulation of Transferrin receptor 1” 6. Invited lecture: 2012, Houston, The Methodist Hospital Research Institute MALDI-TOF Workshop, “Introduction to hepcidin and iron mechanisms” 7. Poster presentation: 2014, Boston, International Society for Stem Cell Research Annual Meeting, “Usp26 Functions as a Negative Regulator of Cellular Reprogramming by Regulating PRC1 Complexes” 8. Oral presentation: 2016, Houston, The Quarterly Investigators Meeting of Dottie and Jimmy C. Adair Myelodysplastic Syndrome Research and Treatment Fund, “Cellular Epigenetic Reprogramming and Differentiation in Myelodysplastic Syndromes”
Ning, Bo CV, Page 4
9. Oral presentation: 2017, Houston, The Quarterly Investigators Meeting of Dottie and Jimmy C. Adair Myelodysplastic Syndrome Research and Treatment Fund, “Mutated genes based precision medicine for MDS therapy” Professional Affiliations Membership: • American Association for Cancer Research (AACR) • International Society for Stem Cell Research (ISSCR) • American Society of Hematology (ASH) Teaching experience Houston Methodist Research Institute, Center for Inflammation and Epigenetic, Houston, TX Research Training Assistant 08/2014–09/2016 • Mentored graduate students from XiangYa hospital, China in research.